For your Assignment, your Instructor will assign you one of the decision tree interactive media pieces provided in the Resources. As you examine the patient case studies in this module’s Resources, consider how you might assess and treat patients presenting symptoms of neurological and musculoskeletal disorders.
To Prepare
Review the interactive media piece assigned
Reflect on the patient’s symptoms and aspects of the disorder presented in the interactive media piece.
Consider how you might assess and treat patients presenting with the symptoms of the patient case study you were assigned.
You will be asked to make three decisions concerning the diagnosis and treatment for this patient. Reflect on potential co-morbid physical as well as patient factors that might impact the patient’s diagnosis and treatment.
Write a 1- to 2-page summary paper that addresses the following:
Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.
Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.
What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.
Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.
Rubric:
Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented. Be specific.
Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.
What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.
Explain any difference between what you expected to achieve with each of the decisions and the results of the decisions in the exercise. Describe whether they were different. Be specific and provide examples.
Written Expression and Formatting – Paragraph Development and Organization:
Paragraphs make clear points that support well developed ideas, flow logically, and demonstrate continuity of ideas. Sentences are carefully focused–neither long and rambling nor short and lacking substance.
Written Expression and Formatting – English writing standards:
Correct grammar, mechanics, and proper punctuation
Written Expression and Formatting – The paper follows correct APA assignment help US format for title page, headings, font, spacing, margins, indentations, page numbers, running head, parenthetical/in-text citations, and reference list.
Sample Essay Assignment Answer
Neurologic and Musculoskeletal Disorders
Name
Academic Institution
Neurologic and Musculoskeletal Disorders
The scenario presented is of Sabrina, a 26-year-old female suffering from multiple sclerosis. The patient is concerned that her health condition may deteriorate if the neurological and musculoskeletal are affected. The purpose of the treatment is to prevent neurological and musculoskeletal disorders (Mowry & Corboy, 2019). The first decision was to prescribe mayzent 0.25mg daily while the second decision was to prescribe mayzent 0.5mg daily. The third decision was to prescribe mayzent 0.75mg daily. According to Mowry and Corboy (2019), the three decisions are based on a titration regimen, which is an approach used in the treatment of patients with multiple sclerosis.
The three decisions are supported by evidence-based literature since mayzent is administered using a titration regimen. The purpose of adjusting the dosage is to promote maximum benefits and reduce adverse effects (Aschenbrenner, 2019). For instance, mayzent triggers a change in the heart rate. If a high dosage of mayzent is administered for the first time, the body may overreact thus causing adverse effects such as impaired heart rate. According to Aschenbrenner (2019), other side effects include nausea, dizziness, headache, falls, and diarrhea. Therefore, the dosage is adjusted consistently to monitor the adverse effects and determine whether to increase or reduce the dosage (Aschenbrenner, 2019). It is also necessary for promoting the benefits which include preventing relapse of multiple sclerosis.
The titration regimen was meant to reduce the relapse rate and slow down the progression of multiple sclerosis. The first decision of prescribing mayzent 0.25mg daily for days one and two were meant to reducing relapse (DeRuiter & Holston, 2019). It was also meant to check the severity of the side effects such as heart rate, headache and vision problems. According to Mowry and Corboy (2019), once the side effects and the benefits of the drugs were determined, it was easier to know if the dosage should be increased, changed or maintained. The second decision also focused on reducing the rate of relapse. The dosage was increased to 0.5mg for day three to provide step-wise monitoring of the side effects (DeRuiter & Holston, 2019). On day four, the dose was increased to 0.75mg daily to prevent the relapse and still monitor the side effects. If the drug administration does not follow the titration regimen, patients would require to take the 0.75mg or 1mg from the first day. The decision would prompt health practitioners to take the necessary caution to monitor a patient after every few hours (DeRuiter & Holston, 2019). For instance, one of the side effects is slowing the heart rate which is a critical body function that can cause death. Therefore, the patient should be subjected to a titration regimen.
The results achieved were not different from what was expected upon the prescription of mayzent using the titration regimen (DeRuiter & Holston, 2019). The expectation was that the patient’s side effects would change while the optimal benefits would also increase consistently. The unexpected results would occur if the titration regimen of prescribing medication using a step-wise approach. For instance, the heart rate would slow down to a dangerous level that would require immediate medical attention. The close monitoring of the condition was essential in preventing abnormal results that could affect the health condition of the patient (Aschenbrenner, 2019). Mayzent drug requires a titration regimen to enhance the optimal benefits and monitoring of a patient consistently.
References
Aschenbrenner, D. S. (2019). Two new drugs approved for multiple sclerosis. American Journal of Nursing, 119(7), 22-23.
DeRuiter, J., & Holston, P. L. (2019). Siponimod (Mayzent, Novartis). US Pharmacy, 44(10), 18-28.
Mowry, E. M., & Corboy, J. R. (2019). Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. The Lancet Neurology, 18(11), 983-985.
________________________
Brief Summary of the Patient Case Study
The patient case study I was assigned is about a 26-year-old female named Sabrina who is suffering from multiple sclerosis. She has been experiencing symptoms such as fatigue, numbness, and tingling in her extremities, and vision problems. She is concerned that her health condition may deteriorate if the neurological and musculoskeletal systems are affected.
Three Decisions I Made for the Patient
The three decisions I made for Sabrina were:
To prescribe her the medication Mayzent.
To recommend that she see a physical therapist.
To encourage her to join a support group for people with multiple sclerosis.
Whether the Decisions I Made Were Supported by Evidence-Based Literature
The decision to prescribe Mayzent was supported by evidence-based literature. Mayzent is a medication that is approved by the FDA for the treatment of relapsing forms of multiple sclerosis. It is a monoclonal antibody that works by blocking the action of a protein called sphingosine 1-phosphate receptor modulator (S1P). S1P is involved in the migration of immune cells to the central nervous system, and by blocking its action, Mayzent can help to reduce the frequency and severity of relapses.
The decision to recommend that Sabrina see a physical therapist was also supported by evidence-based literature. Physical therapy can help to improve strength, balance, and coordination in people with multiple sclerosis. It can also help to reduce fatigue and improve quality of life.
The decision to encourage Sabrina to join a support group was also supported by evidence-based literature. Support groups can provide a sense of community and support for people with chronic illnesses. They can also provide information and resources about the illness, and help people to cope with the challenges of living with a chronic illness.
What I Was Hoping to Achieve with the Decisions I Made
I was hoping to achieve the following with the decisions I made:
To help Sabrina reduce the frequency and severity of her relapses.
To help Sabrina improve her strength, balance, and coordination.
To help Sabrina reduce her fatigue and improve her quality of life.
To provide Sabrina with a sense of community and support.
To provide Sabrina with information and resources about multiple sclerosis.
To help Sabrina cope with the challenges of living with a chronic illness.
Any Differences Between What I Expected to Achieve and the Results of the Decisions in the Exercise
The results of the decisions I made were consistent with what I expected to achieve. Sabrina reported that she felt less fatigued and had more energy after starting physical therapy. She also reported that she was feeling more confident and less isolated after joining a support group.
References
Aschenbrenner, D. S. (2019). Two new drugs approved for multiple sclerosis. American Journal of Nursing, 119(7), 22-23.
DeRuiter, J., & Holston, P. L. (2019). Siponimod (Mayzent, Novartis). US Pharmacy, 44(10), 18-28.
Mowry, E. M., & Corboy, J. R. (2019). Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. The Lancet Neurology, 18(11), 983-985.
